We've made it easier for you to connect! Fill out your NEW profile.
Breastcancer.org is hiring! Read the job posting: Virtual Support Group Facilitator and Community Moderator
Diagnosed Young? We'd love your answers to these questions.
Podcast: Experimental Capivasertib Promising for HR+, HER2- MBC
moderators
Posts: 9,250
Dr. Nicholas Turner explains research looking at capivasertib, a new targeted therapy medicine.
Researchers are always looking for new treatments for advanced-stage breast cancer. Dr. Nicholas Turner explains the results of the CAPitello-291 trial, looking capivasertib, an experimental targeted therapy medicine, in combination with Faslodex (chemical name: fulvestrant) as a treatment for advanced-stage, hormone receptor-positive, HER2-negative breast cancer that has become resistant to the aromatase inhibitors.
Listen to the episode to hear Dr. Turner explain:
- how capivasertib works
- the results of the CAPitello-291 trial
- how capivasertib worked on cancers previously treated with a CDK4/6 inhibitor
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.
Breastcancer.org is hiring! Read the job posting: Virtual Support Group Facilitator and Community Moderator